SEARCH

SEARCH BY CITATION

References

  • 1
    Olapade-Olaopa EO. The expression of a mutant epidermal growth factor receptor in prostatic tumours. Thesis, Department of Surgery, University of Leicester 2000
  • 2
    Dijkman GA & Dubruyne FMJ. Epidemiology of prostate cancer. Eur Urol 1996; 30: 224226
  • 3
    Byrne RL, Leung H & Neal DE. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol 1996; 77: 62733
  • 4
    Maddy SQ, Chisholm GD, Busuttil A & Habib FK. Epidermal growth factor receptors in prostate cancer: correlation with histological differentiation of the tumour. Br J Cancer 1989; 60: 414
  • 5
    Cohen D, Simark R, Fair WR, Melamed J, Scher HI & Cordon-Cardo C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostatic tissue. J Urol 1994; 152: 21204
  • 6
    Moul JW, Maygarden SJ & Ware JL et al. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. J Urol 1996; 155: 9825
  • 7
    Moscatello DK, Holga-Madruga M & Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumours. Cancer Res 1995; 55: 55369
  • 8
    Olapade-Olaopa EO, Moscatello DK & MacKay EH et al. Evidence for the differential expression of a variant EGF receptor in human prostate cancer. Br J Cancer 2000; 82: 18694DOI: 10.1054/bjoc.1999.0898
  • 9
    Olapade-Olaopa EO, Ogunbiyi JO & MacKay EH et al. Further characterisation of storage-related alterations in immunoreactivity of archival tissue sections and its implications for collaborative multi-centre immunohistochemical studies. Appl Immunohistochem Mol Morph 2000; :in press
  • 10
    Newby J, Johnston S, Smith I & Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997; 3: 164351
  • 11
    Montie J. Current prognostic factors for prostate carcinoma. Cancer 1995; 78: 3414
  • 12
    Stattin P, Damber JE, Karlberg L & Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin -fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997; 157: 21922